The Fly | OPTH

Over a week ago

Psychedelic: Helus Pharma reports FY26 financial results

Jul 2, 9:56 AM

Optimi Health completes psilocybin export to Australia

OPTH

Jun 29, 11:16 AM

Opening Day: Kardigan races higher after debut on Nasdaq

Jun 22, 1:29 PM

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

Jun 18, 9:57 AM

Optimi launches standardized microdose psilocybin products for clinical research

OPTH

Jun 16, 12:38 PM

Opening Day: SpaceX jumps on first day of trading, surges past $2T

+11

Jun 15, 11:01 AM

Psychedelic: Optimi Health completes psilocybin export to the UK

Jun 11, 10:15 AM

Optimi Health completes first export of naturally derived psilocybin to the UK

OPTH

Jun 10, 9:18 AM

Optimi Health commences finished ibogaine drug product development

OPTH

Jun 8, 12:57 PM

Optimi Health secures ibogaine supply

OPTH

Jun 8, 8:06 AM

Psychedelic: Enveric initiates IND-enabling genotoxicity studies of EB-003

Jun 4, 10:57 AM

Optimi Health completes commercial production of psilocybin capsules

OPTH

Jun 2, 9:03 AM

Optimi Health reports expanded psychedelic-assisted therapy access in Australia

OPTH

May 29, 8:58 AM

Psychedelic: Optimi Health advances natural psilocybin extract

May 28, 10:19 AM

Opening Day: SpaceX submits S-1 for Nasdaq IPO

+15

May 26, 11:02 AM

Optimi Health opens at $5.50 after Nasdaq uplisting

OPTH

May 20, 11:38 AM

Optimi Health 2.5M share IPO price range $6.00-$8.00

OPTH

Apr 20, 11:44 AM

No more stories

GMP Compliant Production Facilities: Optimi operates a Health Canada licensed, GMP-certified facility for the cultivation and extraction of psilocybin, ensuring high-quality, standardized products suitable for clinical trials and potential pharmaceutical markets.

Extensive Health Canada Dealer's License: The company holds a robust Dealer's License from Health Canada, permitting the possession, production, sale, export, and import of psilocybin and psilocin, providing broad operational flexibility within the regulated market.

Significant Cultivation and Extraction Capacity: Optimi possesses substantial infrastructure for the large-scale cultivation and extraction of psychedelic compounds, positioning it to be a leading B2B supplier for researchers, clinics, and future approved therapeutic applications.

Regulatory Landscape Volatility: The evolving legal and regulatory framework surrounding psychedelic compounds presents significant uncertainty; adverse changes or delays in necessary approvals could severely impact Optimi's operations and market access.

Clinical Trial and Research Outcomes: The success of Optimi's products relies heavily on positive results from ongoing and future clinical trials regarding efficacy, safety, and patient outcomes; unfavorable results could halt product development.

Public Perception and Stigma: Overcoming historical societal stigma and achieving widespread public and medical community acceptance of psychedelic-assisted therapies is crucial for market adoption and commercial success.